- Home
- BE vs GH Comparison
BE vs GH Comparison
Compare BE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- GH
- Stock Information
- Founded
- BE 2001
- GH 2011
- Country
- BE United States
- GH United States
- Employees
- BE N/A
- GH N/A
- Industry
- BE Industrial Machinery/Components
- GH Medical Specialities
- Sector
- BE Energy
- GH Health Care
- Exchange
- BE Nasdaq
- GH Nasdaq
- Market Cap
- BE 5.5B
- GH 4.9B
- IPO Year
- BE 2018
- GH 2018
- Fundamental
- Price
- BE $18.49
- GH $40.18
- Analyst Decision
- BE Buy
- GH Strong Buy
- Analyst Count
- BE 17
- GH 21
- Target Price
- BE $22.74
- GH $52.81
- AVG Volume (30 Days)
- BE 5.4M
- GH 2.3M
- Earning Date
- BE 04-30-2025
- GH 04-30-2025
- Dividend Yield
- BE N/A
- GH N/A
- EPS Growth
- BE N/A
- GH N/A
- EPS
- BE 0.02
- GH N/A
- Revenue
- BE $1,564,579,000.00
- GH $773,996,000.00
- Revenue This Year
- BE $21.99
- GH $23.05
- Revenue Next Year
- BE $19.86
- GH $21.40
- P/E Ratio
- BE $956.78
- GH N/A
- Revenue Growth
- BE 20.95
- GH 28.20
- 52 Week Low
- BE $9.02
- GH $20.14
- 52 Week High
- BE $29.83
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- BE 47.82
- GH 47.02
- Support Level
- BE $18.16
- GH $37.73
- Resistance Level
- BE $19.95
- GH $39.63
- Average True Range (ATR)
- BE 0.87
- GH 1.56
- MACD
- BE 0.01
- GH 0.11
- Stochastic Oscillator
- BE 45.19
- GH 63.25
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.